NYBC Ventures

Based on our deep science and focused on patients in need.

Vitestro develops autonomous blood drawing technology aimed at transforming patient care.

Founded in 2014, Functional Fluidics specializes in developing biomarkers and assays for measuring thrombosis and adhesion formation in whole blood under pulsatile flow. Its primary focus is on improving patient care by providing objective data on red blood cell health through its proprietary blood function assays.

Vittoria Biotherapeutics is a biotechnology company focused on developing gene-edited T-cell therapies to address unmet medical needs in oncology and autoimmune diseases. It utilizes Senza5 technology to enhance the efficacy, safety, and practical utility of cell-based therapeutics, aiming to lower dosing requirements, ease preconditioning regimens, reduce manufacturing failures, and shorten vein-to-vein times. By expanding the potential applications of T-cell therapies, the company seeks to improve patient outcomes across its therapeutic pipeline and advance next-generation cell-based treatments from research toward clinical use.

Aronora is a biotechnology company developing early-stage proprietary biologics, including monoclonal antibodies and enzymes, to treat blood clotting diseases. Its product candidates aim to prevent harmful blood clots without increasing bleeding risks, targeting heart attack and stroke, two leading global causes of death.

Star Therapeutics aims to develop therapies for numerous rare diseases by identifying those with shared biological pathways. This approach enables the creation of single treatments capable of addressing multiple conditions, thereby expanding pharmaceutical pipelines.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

HealthQuest Capital is a growth equity firm based in Redwood City, California, established in 2013. The firm specializes in investing in commercial-stage companies across various sectors of the healthcare industry, including medical devices, biopharmaceuticals, healthcare services, and healthcare information technology. HealthQuest Capital focuses on innovative companies that develop medical technologies, diagnostics, research tools, and digital health solutions, aiming to support advancements that improve healthcare delivery and outcomes. As a Registered Investment Adviser, the firm is committed to fostering growth in the healthcare sector through strategic investments.

KaloCyte Inc., established in 2016 and based in Baltimore, Maryland, is a pre-clinical stage healthcare biotechnology company focused on developing innovative solutions for life-threatening blood loss scenarios. The company's flagship product, ErythroMer, is an artificial red blood cell substitute designed to be dried and bio-inspired, intended for use when stored red blood cells are unavailable or undesirable. This product aims to address critical gaps in trauma care services by providing a demonstrated proof of concept for treating hemorrhage situations effectively.

STRM.BIO is a biotechnology company focused on advancing gene therapy through the innovative use of extracellular vesicles (EVs). By leveraging the natural properties of EVs, which can efficiently deliver nucleic acids and proteins, the company aims to establish a new class of therapeutics that enhance the effectiveness of existing treatments while simplifying the delivery process. STRM.BIO emphasizes safety and practicality in its approach, utilizing EVs as low-immunogenic carriers that can be mass-produced for commercial use. The company's mission is to fulfill the potential of gene therapy by providing patients with more effective and accessible treatment options.

Catena Biosciences specializes in biotechnology, offering protein conjugation services for building biological structures and facilitating medical research. Its proprietary technology enables the attachment of proteins with high selectivity, supporting innovation in autoimmune disorders, oncology, and vaccine development.

Thymmune Therapeutics is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease.

Vega Therapeutics is a clinical-stage biotechnology company focused on developing therapies for rare blood disorders with unmet patient needs. The company advances novel treatments that target Protein S to augment and restore thrombin generation during both initiation and propagation of coagulation, offering hemostatic options for bleeding conditions. By concentrating on mechanisms of coagulation, Vega Therapeutics seeks to address overlooked gaps in current care for patients with uncommon bleeding disorders.